Grace Therapeutics (GRCE) 10% Owner Opaleye Buys 7,849 Shares

What Happened
Opaleye Management, Inc., reported as the investment manager for Opaleye, L.P. (a 10% owner), acquired 7,849 shares of Grace Therapeutics, Inc. (GRCE) in a purchase on 2026-09-29. The shares were purchased at $2.09 per share for a total of approximately $16,404. This filing records a direct buy (transaction code P) rather than a sale or option exercise.

Key Details

• Transaction date: 2026-09-29; Filing date (Form 4): 2026-10-01. The filing appears within the usual SEC reporting window.
• Price and size: 7,849 shares at $2.09 per share; total consideration ~$16,404.
• Shares owned after transaction: Not specified in this Form 4.
• Footnotes: F1 notes the securities are owned directly by Opaleye, L.P.; Opaleye Management, Inc. is the fund’s investment manager and may be deemed to beneficially own the Fund’s securities. F2 states Opaleye Management disclaims beneficial ownership except to the extent of its pecuniary interest.
• Transaction type: Purchase by a 10% owner (institutional/fund-level activity), not an executive insider trade.

Context
Because this involves a 10% owner and its manager, the trade reflects fund-level buying rather than a company officer’s personal decision. Purchases can be of interest to investors as a sign of institutional accumulation, but the footnotes indicate the manager disclaims direct beneficial ownership beyond its economic interest. No options, awards, gifts, or tax-withholding transactions are involved in this filing.